Therapeutic experiences with an abeorphine derivative in Parkinson's disease.
Marked improvement of the clinical state owing to CI 201-678 treatment was seen in six patients; no definite improvement was achieved in three patients. Daily fluctuations were improved in two patients. CI 201-678 demonstrated a good effect against rigidity, impairment of gait and posture, as well as impaired self-care, although daily levodopa dosage was concomitantly reduced. In two patients, CI 201-678 was discontinued because of side-effects, while one patient stopped treatment for reasons not related to the drug. In contrast to apomorphine and other dopamimetic substances, the emetic side-effect of CI 201-678 is minimal (nausea in one patient). no arterial hypotension was not seen. It has to be mentioned that the two drug-related drop-outs were receiving CI 201-678 in a rapidly increasing dosage. It is likely that the side-effects would have been less pronounced if the dosage had been more slowly increased. However, the preliminary results indicate that CI 201-678 is a promising substance for the treatment of patients with predominant rigid-akinetic symptomatology, in combination with levodopa therapy or in the place of levodopa.
D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009048:Motor Skills / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy*
D000978:Antiparkinson Agents; D007211:Indoles; D007980:Levodopa; C047807:CI 201-678